AR099820A1 - Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis c - Google Patents
Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis cInfo
- Publication number
- AR099820A1 AR099820A1 ARP150100859A ARP150100859A AR099820A1 AR 099820 A1 AR099820 A1 AR 099820A1 AR P150100859 A ARP150100859 A AR P150100859A AR P150100859 A ARP150100859 A AR P150100859A AR 099820 A1 AR099820 A1 AR 099820A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- compounds
- substituted
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, que incluyen sus sales, además de composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (HCV) y pueden ser útiles en el tratamiento de los pacientes infectados con HCV. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), que incluye sales de este aceptables desde el punto de vista farmacéutico, en donde Z es C-R⁵ o N; R⁰ es hidrógeno; R¹ es metilo; R² es fenilo que se sustituye independientemente con 0 - 2 halo o metoxi, o es para sustituido con W-Ar; W es -O- o -NH-; Ar es fenilo o para-halofenilo; R³ es hidrógeno, fluoro o cloro; R⁴, R⁵, y R⁶ se seleccionan independientemente del grupo de hidrógeno, halo, alquilo, haloalquilo, alcoxi y perdeuteroalcoxi; R⁷ᵃ, R⁷ᵇ se seleccionan, cada uno independientemente, del grupo de hidrógeno, alquilo, cicloalquilo, y Ar¹ o juntos R⁷ᵃ y R⁷ᵇ forman un anillo carbocíclico de 3 - 7 miembros; R⁸ es hidrógeno, Ar¹ es fenilo, un anillo heteroaromático de 5 miembros o un anillo heteroaromático de 6 miembros; R⁹ es hidrógeno, halo, R²⁰¹, OR²⁰², NR²⁰³R²⁰⁴; R²⁰¹ es alquilo, alquenilo o C₁₋₄ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro; R²⁰² es C₁₋₃ alquilo o C₁₋₃ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro; R²⁰³ es hidrógeno; y R²⁰⁴ es C₁₋₃ alquilo o C₁₋₃ hidroxialquilo o es C₁₋₃ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968763P | 2014-03-21 | 2014-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099820A1 true AR099820A1 (es) | 2016-08-17 |
Family
ID=52808191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100859A AR099820A1 (es) | 2014-03-21 | 2015-03-20 | Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9249152B2 (es) |
| EP (1) | EP3119785B1 (es) |
| JP (1) | JP2017509700A (es) |
| KR (1) | KR20160126085A (es) |
| CN (1) | CN106459070A (es) |
| AR (1) | AR099820A1 (es) |
| AU (1) | AU2015231139A1 (es) |
| CA (1) | CA2943526A1 (es) |
| CL (1) | CL2016002361A1 (es) |
| EA (1) | EA201691777A1 (es) |
| ES (1) | ES2688554T3 (es) |
| IL (1) | IL247830A0 (es) |
| MX (1) | MX2016012104A (es) |
| PE (1) | PE20161224A1 (es) |
| SG (1) | SG11201607750PA (es) |
| TW (1) | TW201620914A (es) |
| WO (1) | WO2015143255A1 (es) |
| ZA (1) | ZA201606478B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9920036B2 (en) * | 2014-03-21 | 2018-03-20 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C |
| ES2899581T3 (es) * | 2015-12-07 | 2022-03-14 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones para estos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| CN101910145A (zh) | 2008-02-14 | 2010-12-08 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CN102906089A (zh) * | 2010-03-10 | 2013-01-30 | 百时美施贵宝公司 | 用于治疗丙型肝炎的化合物 |
| BR112013009789A2 (pt) | 2010-10-26 | 2016-07-19 | Presidio Pharmaceuticals Inc | inibidores do vírus da hepatite c |
-
2015
- 2015-03-20 US US14/663,497 patent/US9249152B2/en active Active
- 2015-03-20 CN CN201580024715.3A patent/CN106459070A/zh active Pending
- 2015-03-20 EP EP15714137.5A patent/EP3119785B1/en not_active Not-in-force
- 2015-03-20 PE PE2016001648A patent/PE20161224A1/es not_active Application Discontinuation
- 2015-03-20 JP JP2017501122A patent/JP2017509700A/ja active Pending
- 2015-03-20 EA EA201691777A patent/EA201691777A1/ru unknown
- 2015-03-20 CA CA2943526A patent/CA2943526A1/en not_active Abandoned
- 2015-03-20 ES ES15714137.5T patent/ES2688554T3/es active Active
- 2015-03-20 KR KR1020167028891A patent/KR20160126085A/ko unknown
- 2015-03-20 MX MX2016012104A patent/MX2016012104A/es unknown
- 2015-03-20 SG SG11201607750PA patent/SG11201607750PA/en unknown
- 2015-03-20 AU AU2015231139A patent/AU2015231139A1/en not_active Abandoned
- 2015-03-20 WO PCT/US2015/021638 patent/WO2015143255A1/en active Application Filing
- 2015-03-20 AR ARP150100859A patent/AR099820A1/es unknown
- 2015-03-20 TW TW104109071A patent/TW201620914A/zh unknown
-
2016
- 2016-09-15 IL IL247830A patent/IL247830A0/en unknown
- 2016-09-20 CL CL2016002361A patent/CL2016002361A1/es unknown
- 2016-09-20 ZA ZA2016/06478A patent/ZA201606478B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2688554T3 (es) | 2018-11-05 |
| SG11201607750PA (en) | 2016-10-28 |
| AU2015231139A1 (en) | 2016-11-03 |
| TW201620914A (zh) | 2016-06-16 |
| EP3119785B1 (en) | 2018-08-15 |
| CA2943526A1 (en) | 2015-09-24 |
| MX2016012104A (es) | 2016-12-09 |
| KR20160126085A (ko) | 2016-11-01 |
| CN106459070A (zh) | 2017-02-22 |
| CL2016002361A1 (es) | 2017-04-21 |
| WO2015143255A1 (en) | 2015-09-24 |
| US20150266886A1 (en) | 2015-09-24 |
| PE20161224A1 (es) | 2016-11-12 |
| ZA201606478B (en) | 2018-05-30 |
| IL247830A0 (en) | 2016-11-30 |
| US9249152B2 (en) | 2016-02-02 |
| JP2017509700A (ja) | 2017-04-06 |
| EA201691777A1 (ru) | 2016-12-30 |
| EP3119785A1 (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |